LifeMine Therapeutics Inc. has secured $263 million in a Series C financing round, marking a significant step in its clinical-stage development. This funding will accelerate the advancement of its lead program, LIFE-001, and its broader pipeline of transplantation and immunology therapies. The company's proprietary Top-Down Drug Discovery™ platform leverages digital genomic search technology from fungi to identify novel precision medicines.